No-Deal Brexit Will Require New U.S.-U.K. Drug Inspection Pact

December 12, 2018

Drugmakers like GlaxosmithKline and Pfizer with plants in the U.K. may have to wait for new agreement on how their U.S.-bound drugs are inspected after Brexit, but observers expect a short wait if there is a lapse.

Related Stories